Page last updated: 2024-11-04

n-(3-(aminomethyl)benzyl)acetamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(3-(aminomethyl)benzyl)acetamidine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1433
CHEMBL ID107251
CHEMBL ID544788
CHEBI ID90721
SCHEMBL ID4467
MeSH IDM0273657

Synonyms (78)

Synonym
SMP2_000243
BIO1_000427
BIO2_000791
BIO1_001405 ,
tocris-1415
NCGC00016095-01
BIO1_000916
NCGC00025154-01
BIO2_000311
lopac-w-4262
LOPAC0_001258
IDI1_034061
BSPBIO_001591
BCBCMAP01_000134
14W ,
n-(3-(aminomethyl)benzyl)acetamidine
DB02044
n-[3-(aminomethyl)benzyl]acetamidine
NCGC00025154-04
1400w
NCGC00025154-03
KBIOSS_000311
KBIO2_005447
KBIOGR_000311
KBIO3_000621
KBIO2_002879
KBIO2_000311
KBIO3_000622
NCGC00025154-02
NCGC00025154-05
n-((3-(aminomethyl)phenyl)methyl)ethanimidamide
HMS1989P13
n-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide
[n-(3-aminomethyl)benzylactamidine]
n-(3-aminomethyl)benzylacetimidamide
n-(3-(aminomethyl)benzyl)acetimidamide
bdbm50226527
CHEMBL107251 ,
chebi:90721 ,
HMS1791P13
HMS1361P13
CHEMBL544788 ,
bdbm50065805
n-(3-aminomethyl-benzyl)-acetamidine
n'-[[3-(aminomethyl)phenyl]methyl]ethanimidamide
n-[3-(aminomethyl)benzyl]ethanimidamide
AKOS006277318
CCG-205332
NCGC00016095-04
NCGC00016095-06
NCGC00016095-03
NCGC00016095-02
NCGC00016095-05
n-{[3-(aminomethyl)phenyl]methyl}ethanimidamide
w 1400
(e)-n'-{[3-(aminomethyl)phenyl]methyl}ethenimidamide
gtpl5102
SCHEMBL4467
n-(3-(aminomethyl)benzyl)-acetamidine
W1400 ,
180001-34-7
n-[[3-(aminomethyl)phenyl]methyl]ethanimidamide
ethanimidamide,n-[[3-(aminomethyl)phenyl]methyl]-
n-3-aminomethyl-benzyl-acetamidine
unii-m1vb8vp8oh
m1vb8vp8oh ,
1400w (dihydrochloride)
(1z)-n-[3-(aminomethyl)benzyl]ethanimidamide
1400w2hcl
FT-0708248
BCP24904
n-(3-(aminomethyl)benzyl)acetimidine
Q27070773
BRD-K30237152-300-01-7
ethanimidamide, n-[[3-(aminomethyl)phenyl]methyl]-
ethanimidamide, n-((3-(aminomethyl)phenyl)methyl)-
n-((3-(aminomethyl)phenyl)methyl)-ethanimidamide
DTXSID201290729

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Nitric oxide can combine with superoxide to form peroxynitrite, a molecule that may participate in the toxic mechanisms of hepatotoxins, such as acetaminophen and bacterial endotoxin."( iNOS-null mice are not resistant to cadmium chloride-induced hepatotoxicity.
Harstad, EB; Klaassen, CD, 2002
)
0.31
" Cardiotoxicity is a major side effect of these drugs and limit their use."( Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity.
Acikel, C; Arpaci, F; Ataergin, S; Demirbas, S; Ersoz, N; Korkmaz, A; Kurt, B; Kurt, YG; Kuzhan, O; Oter, S; Ozet, A; Ozler, M; Oztas, Y; Ozturk, B; Ozturk, M; Topal, T; Uysal, B; Yasar, M, 2011
)
0.37
"4 mg) caused no significant toxic ocular effects in rabbit eyes."( TOWARDS A TREATMENT FOR DIABETIC RETINOPATHY: Intravitreal Toxicity and Preclinical Safety Evaluation of Inducible Nitric Oxide Synthase Inhibitors.
Bennett, LD; Birch, DG; Carr, BC; Emigh, CE; Nguyen, C; Pansick, AD, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" The high percentage of cell death with SNP+NAC suggests that NAC forms S-nitrosothiols with NO, resulting in an increase in the bioavailability of NO."( Nitric oxide induces apoptosis in the fat body cell line IPLB-LdFB from the insect Lymantria dispar.
Barbieri, D; Franchini, A; Malagoli, D; Ottaviani, E, 2001
)
0.31
" The cell-based assay provides more information than in vitro assays regarding the bioavailability of NOS inhibitors, and it is suitable for high-throughput screening."( A cellular model for screening neuronal nitric oxide synthase inhibitors.
Fang, J; Silverman, RB, 2009
)
0.35
" In conclusion, while NO bioavailability in mTALs is reduced during diabetes, free radical scavenging with tempol unmasks increased NO production that involves PP2B-dependent activation of NOS1 and NOS2."( PP2B-dependent NO production in the medullary thick ascending limb during diabetes.
Carmines, PK; Foster, JM; Pollock, JS, 2009
)
0.35
" The present study demonstrated that iNOS-derived superoxide generation was reduced, and that the NO bioavailability was increased, by treatment with the NOS-cofactor, tetrahydrobiopterin (BH4), before I/R in the hearts isolated from diabetic rats."( Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart.
Fujita, M; Ito, S; Iwasaka, T; Katano, T; Okazaki, T; Otani, H; Shimazu, T; Yoshioka, K, 2011
)
0.37
" Using a murine model of mild HHcy (cbs(+/-) mouse), we show that 3-NT is significantly elevated in cerebral microvessels with concomitant reductions in serum NO bioavailability as compared with wild-type littermate controls (cbs(+/+))."( Nitrative stress in cerebral endothelium is mediated by mGluR5 in hyperhomocysteinemia.
Banks, WA; Beard, RS; Bearden, SE; Chen, CH; Ercal, N; Erickson, MA; Mayo, JN; Price, TO, 2012
)
0.38
" This pre-treatment resulted in full protection of contractility, decreased production of iNOS and ADMA and normalized the bioavailability of NO in the I/R hearts."( A drug cocktail for protecting against ischemia-reperfusion injury.
Bil-Lula, I; Krzywonos-Zawadzka, A; Sawicki, G; Wozniak, M, 2020
)
0.56
" Additionally, it is widely accepted that diabetes impairs endothelial nitric oxide synthase (eNOS) activity, resulting in diminished nitric oxide (NO) bioavailability and consequent endothelial cell dysfunction."( H9c2 Cardiomyocytes under Hypoxic Stress: Biological Effects Mediated by Sentinel Downstream Targets.
Ambrosio, P; Boccellino, M; D'ambrosio, L; Di Domenico, M; Di Zazzo, E; Feola, A; Frati, G; Galasso, G; Lama, S; Quagliuolo, L; Schiavon, S; Stiuso, P; Vecchio, D, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" These data suggest that the compound has been administered using an appropriate dosing regimen for iNOS inhibition in the rat lung."( Pharmacological assessment of the nitric-oxide synthase isoform involved in eosinophilic inflammation in a rat model of sephadex-induced airway inflammation.
Battram, CH; Belvisi, MG; Birrell, MA; Foster, ML; Haddad, el-B; McCluskie, K; Webber, SE; Yacoub, MH, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
EC 1.14.13.39 (nitric oxide synthase) inhibitorAn EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of nitric oxide synthase (EC 1.14.13.39).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
aralkylamineAn alkylamine in which the alkyl group is substituted by an aromatic group.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency0.31620.02827.055915.8489AID895; AID928
DNA polymerase kappa isoform 1Homo sapiens (human)Potency29.93490.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency2.51190.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nitric oxide synthase, endothelialBos taurus (cattle)IC50 (µMol)611.33331.20003.40007.0000AID1233820; AID1358814; AID528192
Nitric oxide synthase, endothelialHomo sapiens (human)IC50 (µMol)485.06670.07202.58738.7000AID1661306; AID1823694; AID345879
Nitric oxide synthase, brainHomo sapiens (human)IC50 (µMol)4.89000.03502.711910.0000AID1661305; AID1823693
Nitric oxide synthase, brainHomo sapiens (human)Ki7.30000.01501.18117.3000AID405517
Nitric oxide synthase, brain Rattus norvegicus (Norway rat)IC50 (µMol)7.55000.04004.16389.3000AID1358816; AID528191
Nitric oxide synthase, inducibleMus musculus (house mouse)IC50 (µMol)0.17700.00103.39119.6000AID1233819; AID1358813; AID528190
Nitric oxide synthase, inducibleHomo sapiens (human)IC50 (µMol)0.13950.00022.319010.0000AID1661304; AID1823692; AID345878
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (92)

Processvia Protein(s)Taxonomy
arginine catabolic processNitric oxide synthase, endothelialBos taurus (cattle)
nitric oxide biosynthetic processNitric oxide synthase, endothelialBos taurus (cattle)
mitochondrion organizationNitric oxide synthase, endothelialBos taurus (cattle)
blood coagulationNitric oxide synthase, endothelialBos taurus (cattle)
positive regulation of guanylate cyclase activityNitric oxide synthase, endothelialBos taurus (cattle)
cellular response to laminar fluid shear stressNitric oxide synthase, endothelialBos taurus (cattle)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsNitric oxide synthase, endothelialBos taurus (cattle)
negative regulation of leukocyte cell-cell adhesionNitric oxide synthase, endothelialBos taurus (cattle)
positive regulation of gene expressionNitric oxide synthase, endothelialHomo sapiens (human)
angiogenesisNitric oxide synthase, endothelialHomo sapiens (human)
ovulation from ovarian follicleNitric oxide synthase, endothelialHomo sapiens (human)
in utero embryonic developmentNitric oxide synthase, endothelialHomo sapiens (human)
blood vessel remodelingNitric oxide synthase, endothelialHomo sapiens (human)
regulation of sodium ion transportNitric oxide synthase, endothelialHomo sapiens (human)
regulation of the force of heart contraction by chemical signalNitric oxide synthase, endothelialHomo sapiens (human)
regulation of systemic arterial blood pressure by endothelinNitric oxide synthase, endothelialHomo sapiens (human)
aortic valve morphogenesisNitric oxide synthase, endothelialHomo sapiens (human)
pulmonary valve morphogenesisNitric oxide synthase, endothelialHomo sapiens (human)
endocardial cushion morphogenesisNitric oxide synthase, endothelialHomo sapiens (human)
arginine catabolic processNitric oxide synthase, endothelialHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, endothelialHomo sapiens (human)
potassium ion transportNitric oxide synthase, endothelialHomo sapiens (human)
calcium ion transportNitric oxide synthase, endothelialHomo sapiens (human)
mitochondrion organizationNitric oxide synthase, endothelialHomo sapiens (human)
regulation of blood pressureNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of cell population proliferationNitric oxide synthase, endothelialHomo sapiens (human)
response to heatNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of platelet activationNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of muscle hyperplasiaNitric oxide synthase, endothelialHomo sapiens (human)
smooth muscle hyperplasiaNitric oxide synthase, endothelialHomo sapiens (human)
removal of superoxide radicalsNitric oxide synthase, endothelialHomo sapiens (human)
lung developmentNitric oxide synthase, endothelialHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, endothelialHomo sapiens (human)
regulation of nervous system processNitric oxide synthase, endothelialHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayNitric oxide synthase, endothelialHomo sapiens (human)
response to fluid shear stressNitric oxide synthase, endothelialHomo sapiens (human)
vasodilationNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of potassium ion transportNitric oxide synthase, endothelialHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNitric oxide synthase, endothelialHomo sapiens (human)
endothelial cell migrationNitric oxide synthase, endothelialHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, endothelialHomo sapiens (human)
positive regulation of Notch signaling pathwayNitric oxide synthase, endothelialHomo sapiens (human)
positive regulation of angiogenesisNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of smooth muscle cell proliferationNitric oxide synthase, endothelialHomo sapiens (human)
homeostasis of number of cells within a tissueNitric oxide synthase, endothelialHomo sapiens (human)
establishment of localization in cellNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of calcium ion transportNitric oxide synthase, endothelialHomo sapiens (human)
ventricular septum morphogenesisNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of biomineral tissue developmentNitric oxide synthase, endothelialHomo sapiens (human)
blood vessel diameter maintenanceNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsNitric oxide synthase, endothelialHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, endothelialHomo sapiens (human)
response to hormoneNitric oxide synthase, endothelialHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, endothelialHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, endothelialHomo sapiens (human)
response to hypoxiaNitric oxide synthase, brainHomo sapiens (human)
regulation of sodium ion transportNitric oxide synthase, brainHomo sapiens (human)
arginine catabolic processNitric oxide synthase, brainHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, brainHomo sapiens (human)
striated muscle contractionNitric oxide synthase, brainHomo sapiens (human)
myoblast fusionNitric oxide synthase, brainHomo sapiens (human)
response to heatNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transport into cytosolNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingNitric oxide synthase, brainHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, brainHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNitric oxide synthase, brainHomo sapiens (human)
multicellular organismal response to stressNitric oxide synthase, brainHomo sapiens (human)
xenobiotic catabolic processNitric oxide synthase, brainHomo sapiens (human)
vasodilationNitric oxide synthase, brainHomo sapiens (human)
negative regulation of potassium ion transportNitric oxide synthase, brainHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, brainHomo sapiens (human)
positive regulation of DNA-templated transcriptionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINitric oxide synthase, brainHomo sapiens (human)
negative regulation of hydrolase activityNitric oxide synthase, brainHomo sapiens (human)
negative regulation of serotonin uptakeNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transportNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contractionNitric oxide synthase, brainHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityNitric oxide synthase, brainHomo sapiens (human)
cellular response to growth factor stimulusNitric oxide synthase, brainHomo sapiens (human)
positive regulation of the force of heart contractionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayNitric oxide synthase, brainHomo sapiens (human)
positive regulation of sodium ion transmembrane transportNitric oxide synthase, brainHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelNitric oxide synthase, brainHomo sapiens (human)
positive regulation of membrane repolarization during ventricular cardiac muscle cell action potentialNitric oxide synthase, brainHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, brainHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, brainHomo sapiens (human)
response to hormoneNitric oxide synthase, brainHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, brainHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, brainHomo sapiens (human)
response to hypoxiaNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of leukocyte mediated cytotoxicityNitric oxide synthase, inducibleHomo sapiens (human)
innate immune response in mucosaNitric oxide synthase, inducibleHomo sapiens (human)
arginine catabolic processNitric oxide synthase, inducibleHomo sapiens (human)
superoxide metabolic processNitric oxide synthase, inducibleHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, inducibleHomo sapiens (human)
circadian rhythmNitric oxide synthase, inducibleHomo sapiens (human)
response to bacteriumNitric oxide synthase, inducibleHomo sapiens (human)
negative regulation of gene expressionNitric oxide synthase, inducibleHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, inducibleHomo sapiens (human)
prostaglandin secretionNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of interleukin-6 productionNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of interleukin-8 productionNitric oxide synthase, inducibleHomo sapiens (human)
regulation of cell population proliferationNitric oxide synthase, inducibleHomo sapiens (human)
negative regulation of protein catabolic processNitric oxide synthase, inducibleHomo sapiens (human)
defense response to bacteriumNitric oxide synthase, inducibleHomo sapiens (human)
regulation of cellular respirationNitric oxide synthase, inducibleHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, inducibleHomo sapiens (human)
regulation of insulin secretionNitric oxide synthase, inducibleHomo sapiens (human)
defense response to Gram-negative bacteriumNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of killing of cells of another organismNitric oxide synthase, inducibleHomo sapiens (human)
cellular response to lipopolysaccharideNitric oxide synthase, inducibleHomo sapiens (human)
cellular response to type II interferonNitric oxide synthase, inducibleHomo sapiens (human)
cellular response to xenobiotic stimulusNitric oxide synthase, inducibleHomo sapiens (human)
regulation of cytokine production involved in inflammatory responseNitric oxide synthase, inducibleHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, inducibleHomo sapiens (human)
response to hormoneNitric oxide synthase, inducibleHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, inducibleHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, inducibleHomo sapiens (human)
inflammatory responseNitric oxide synthase, inducibleHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, inducibleHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
nitric-oxide synthase activityNitric oxide synthase, endothelialBos taurus (cattle)
calmodulin bindingNitric oxide synthase, endothelialBos taurus (cattle)
heme bindingNitric oxide synthase, endothelialBos taurus (cattle)
metal ion bindingNitric oxide synthase, endothelialBos taurus (cattle)
NADP bindingNitric oxide synthase, endothelialBos taurus (cattle)
actin monomer bindingNitric oxide synthase, endothelialHomo sapiens (human)
nitric-oxide synthase activityNitric oxide synthase, endothelialHomo sapiens (human)
protein bindingNitric oxide synthase, endothelialHomo sapiens (human)
calmodulin bindingNitric oxide synthase, endothelialHomo sapiens (human)
FMN bindingNitric oxide synthase, endothelialHomo sapiens (human)
heme bindingNitric oxide synthase, endothelialHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, endothelialHomo sapiens (human)
arginine bindingNitric oxide synthase, endothelialHomo sapiens (human)
cadmium ion bindingNitric oxide synthase, endothelialHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, endothelialHomo sapiens (human)
NADP bindingNitric oxide synthase, endothelialHomo sapiens (human)
scaffold protein bindingNitric oxide synthase, endothelialHomo sapiens (human)
nitric-oxide synthase activityNitric oxide synthase, brainHomo sapiens (human)
calcium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
protein bindingNitric oxide synthase, brainHomo sapiens (human)
calmodulin bindingNitric oxide synthase, brainHomo sapiens (human)
FMN bindingNitric oxide synthase, brainHomo sapiens (human)
sodium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
heme bindingNitric oxide synthase, brainHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, brainHomo sapiens (human)
arginine bindingNitric oxide synthase, brainHomo sapiens (human)
transmembrane transporter bindingNitric oxide synthase, brainHomo sapiens (human)
cadmium ion bindingNitric oxide synthase, brainHomo sapiens (human)
calcium-dependent protein bindingNitric oxide synthase, brainHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, brainHomo sapiens (human)
NADP bindingNitric oxide synthase, brainHomo sapiens (human)
scaffold protein bindingNitric oxide synthase, brainHomo sapiens (human)
nitric-oxide synthase activityNitric oxide synthase, inducibleHomo sapiens (human)
protein bindingNitric oxide synthase, inducibleHomo sapiens (human)
calmodulin bindingNitric oxide synthase, inducibleHomo sapiens (human)
FMN bindingNitric oxide synthase, inducibleHomo sapiens (human)
heme bindingNitric oxide synthase, inducibleHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, inducibleHomo sapiens (human)
arginine bindingNitric oxide synthase, inducibleHomo sapiens (human)
protein homodimerization activityNitric oxide synthase, inducibleHomo sapiens (human)
metal ion bindingNitric oxide synthase, inducibleHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, inducibleHomo sapiens (human)
NADP bindingNitric oxide synthase, inducibleHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
Golgi apparatusNitric oxide synthase, endothelialBos taurus (cattle)
cytoskeletonNitric oxide synthase, endothelialBos taurus (cattle)
caveolaNitric oxide synthase, endothelialBos taurus (cattle)
Golgi membraneNitric oxide synthase, endothelialHomo sapiens (human)
nucleusNitric oxide synthase, endothelialHomo sapiens (human)
cytoplasmNitric oxide synthase, endothelialHomo sapiens (human)
Golgi apparatusNitric oxide synthase, endothelialHomo sapiens (human)
cytosolNitric oxide synthase, endothelialHomo sapiens (human)
cytoskeletonNitric oxide synthase, endothelialHomo sapiens (human)
plasma membraneNitric oxide synthase, endothelialHomo sapiens (human)
caveolaNitric oxide synthase, endothelialHomo sapiens (human)
endocytic vesicle membraneNitric oxide synthase, endothelialHomo sapiens (human)
nucleusNitric oxide synthase, endothelialHomo sapiens (human)
plasma membraneNitric oxide synthase, endothelialHomo sapiens (human)
cytosolNitric oxide synthase, endothelialHomo sapiens (human)
photoreceptor inner segmentNitric oxide synthase, brainHomo sapiens (human)
nucleoplasmNitric oxide synthase, brainHomo sapiens (human)
cytoplasmNitric oxide synthase, brainHomo sapiens (human)
mitochondrionNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
cytoskeletonNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
sarcoplasmic reticulumNitric oxide synthase, brainHomo sapiens (human)
sarcolemmaNitric oxide synthase, brainHomo sapiens (human)
dendritic spineNitric oxide synthase, brainHomo sapiens (human)
membrane raftNitric oxide synthase, brainHomo sapiens (human)
synapseNitric oxide synthase, brainHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, brainHomo sapiens (human)
cell peripheryNitric oxide synthase, brainHomo sapiens (human)
protein-containing complexNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
postsynaptic densityNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
nucleusNitric oxide synthase, brainHomo sapiens (human)
nucleusNitric oxide synthase, inducibleHomo sapiens (human)
nucleoplasmNitric oxide synthase, inducibleHomo sapiens (human)
cytoplasmNitric oxide synthase, inducibleHomo sapiens (human)
peroxisomeNitric oxide synthase, inducibleHomo sapiens (human)
peroxisomal matrixNitric oxide synthase, inducibleHomo sapiens (human)
cytosolNitric oxide synthase, inducibleHomo sapiens (human)
cortical cytoskeletonNitric oxide synthase, inducibleHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, inducibleHomo sapiens (human)
plasma membraneNitric oxide synthase, inducibleHomo sapiens (human)
nucleusNitric oxide synthase, inducibleHomo sapiens (human)
cytosolNitric oxide synthase, inducibleHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1661316Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation at 500 uM after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.
AID315141Selectivity for iNOS to nNOS2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID345879Inhibition of eNOS in LPS treated human THP1 cell homogenate assessed as conversion of L-[2,3-3H]arginine to L-[2,3-3H]citrulline pre-incubated 1 hr before LPS challenge by whole cell assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Synthesis, biological evaluation, and docking studies of N-substituted acetamidines as selective inhibitors of inducible nitric oxide synthase.
AID454667Antioxidant activity assessed as nitric oxide scavenging activity in SNP solution at 10 uM in presence of light after 60 mins2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Furo[3',2':3,4]naphtho[1,2-d]imidazole derivatives as potential inhibitors of inflammatory factors in sepsis.
AID1661304Inhibition of recombinant N-terminal His-tagged human iNOS expressed in Escherichia coli using L-arginine as substrate preincubated for 15 mins followed by NADPH addition and measured after 20 mins by OPA/NAC reagent based HPLC-fluorimetric analysis2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.
AID1358820Cytotoxicity against rat CTX/TNA2 cells assessed as inhibition of cell proliferation up to 72 hrs by MTT assay2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1358817Selectivity ratio of IC50 for recombinant rat nNOS to IC50 for recombinant mouse iNOS2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID528192Inhibition of bovine eNOS assessed as nitric oxide mediated oxidation of oxyhemoglobin to methemoglobin2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.
AID428583Inhibition of human eNOS assessed as residual activity at 100 uM by Griess assay relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases.
AID345880Selectivity ratio of IC50 for human eNOS to IC50 for human iNOS2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Synthesis, biological evaluation, and docking studies of N-substituted acetamidines as selective inhibitors of inducible nitric oxide synthase.
AID428581Inhibition of human iNOS expressed in insect Sf9 cells assessed as residual activity at 100 uM by Griess assay relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases.
AID428582Inhibition of mouse iNOS expressed in insect Sf9 cells assessed as residual activity at 100 uM by Griess assay relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases.
AID333456Antiinflammatory activity against mouse N9 cells assessed as inhibition of LPS/IFN-gamma-induced nitrite accumulation after 24 hrs2004Journal of natural products, Nov, Volume: 67, Issue:11
Anti-inflammatory phloroglucinols and terpenoids from Garcinia subelliptica.
AID1358815Selectivity index, ratio of IC50 for recombinant bovine eNOS to IC50 for recombinant mouse iNOS2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID132832Inhibitory effect of compound on the accumulation of NO2 in the culture media of N9 cells in response to LPS/IFN-gamma2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Anti-inflammatory flavonoids and pterocarpanoid from Crotalaria pallida and C. assamica.
AID1661305Inhibition of recombinant human nNOS expressed in Escherichia coli using L-arginine as substrate preincubated for 15 mins followed by NADPH addition and measured after 20 mins by OPA/NAC reagent based HPLC-fluorimetric analysis2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.
AID1358826Cytotoxicity against rat C6 cells assessed as cell proliferation at 1 mM after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1358830Cytotoxicity against rat C6 cells assessed as cell proliferation at 0.5 mM after 48 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1661306Inhibition of human eNOS using L-argininge as substrate preincubated for 15 mins followed by NADPH addition and measured after 20 mins by OPA/NAC reagent based HPLC analysis2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.
AID1823694Inhibition of human eNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr
AID345878Inhibition of iNOS in LPS treated human THP1 cell homogenate assessed as conversion of L-[2,3-3H]arginine to L-[2,3-3H]citrulline pre-incubated 1 hr before LPS challenge by whole cell assay2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Synthesis, biological evaluation, and docking studies of N-substituted acetamidines as selective inhibitors of inducible nitric oxide synthase.
AID428580Inhibition of rat recombinant nNOS expressed in insect Sf9 cells assessed as residual activity at 100 uM by Griess assay relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases.
AID1823695Selectivity ratio of IC50 for human nNOS to IC50 for human iNOS
AID1358816Inhibition of recombinant rat nNOS using [3H]L-arginine as substrate preincubated for 15 mins followed by NADPH addition measured after 20 mins in presence of FMN/FAD by liquid scintillation counting method2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID67989Selectivity index which is the ratio of the Ki or IC50 values of recombinant bovine eNOS (Endothelial nitric oxide synthase) / recombinant murine iNOS (Inducible nitric oxide synthase)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase.
AID1358828Cytotoxicity against rat C6 cells assessed as cell proliferation at 2 mM after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1358827Cytotoxicity against rat C6 cells assessed as cell proliferation at 1.5 mM after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID528194Selectivity ratio, ratio of IC50 for bovine eNOS to IC50 for rat brain nNOS2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.
AID1358822Cytotoxicity against rat CTX/TNA2 cells assessed as inhibition of cell proliferation at 2 mM after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID751331Antiinflammatory activity in mouse RAW264.7 cells assessed as downregulation of LPS-induced iNOS mRNA expression at 2 uM incubated for 2 hrs prior to LPS challenge measured after 9 hrs by RT-PCR analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID358218Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as nitrite accumulation after 20 hrs by fluorimetry2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID528191Inhibition of rat brain nNOS assessed as nitric oxide mediated oxidation of oxyhemoglobin to methemoglobin2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.
AID751338Induction of nitric oxide scavenging activity assessed as nitrite level at 10 uM at room temperature after 60 mins by Griess assay in presence of light and SNP2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID751340Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1823696Selectivity ratio of IC50 for human eNOS to IC50 for human iNOS
AID1233819Inhibition of mouse recombinant iNOS using [3H]L-arginine substrate assessed as formation of [3H]L-citruline by liquid scintillation counting analysis2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Selective Acetamidine-Based Nitric Oxide Synthase Inhibitors: Synthesis, Docking, and Biological Studies.
AID67988Selectivity index which is the ratio of the Ki or IC50 values of recombinant bovine Endothelial nitric oxide synthase and bovine brain nNOS (Neuronal nitric oxide synthase)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase.
AID528190Inhibition of mouse macrophage iNOS assessed as nitric oxide mediated oxidation of oxyhemoglobin to methemoglobin2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.
AID428579Inhibition of human nNOS assessed as residual activity at 100 uM by Griess assay relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases.
AID1233821Selectivity ratio of IC50 for bovine recombinant iNOS to IC50 for mouse recombinant iNOS2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Selective Acetamidine-Based Nitric Oxide Synthase Inhibitors: Synthesis, Docking, and Biological Studies.
AID1358832Cytotoxicity against rat C6 cells assessed as cell proliferation at 0.75 mM after 72 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1358829Cytotoxicity against rat C6 cells assessed as inhibition of cell proliferation after 24 to 48 hrs by MTT assay2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID337053Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production pretreated 1 hr before LPS challenge2003Journal of natural products, Mar, Volume: 66, Issue:3
Anti-inflammatory constituents and new pterocarpanoid of Crotalaria pallida.
AID1823693Inhibition of human nNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr
AID358220Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as PGE2 accumulation after 20 hrs by RIA2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID1823697Effective permeability of compound in PBS buffer at pH 7.4 at 200 uM incubated for 17 hrs by PAMPA-BBB assay
AID1358821Cytotoxicity against rat CTX/TNA2 cells assessed as inhibition of cell proliferation at 1.5 mM after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID751334Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS expression at 0.5 to 2 uM incubated for 2 hrs prior to LPS challenge measured after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID315140Selectivity for iNOS to eNOS2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID418482Inhibition of LPS-induced nitric oxide generation in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by Griess method2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors.
AID613475Inhibition of LPS-stimulated iNOS protein expression in mouse J774 cells at 1000 uM by RT-PCR analysis2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives.
AID707107Inhibition of iNOS in mouse RAW264.7 cells at 50 ug/ml2012Journal of natural products, May-25, Volume: 75, Issue:5
Inhibition of NF-κB-dependent cytokine and inducible nitric oxide synthesis by the macrocyclic ellagitannin oenothein B in TLR-stimulated RAW 264.7 macrophages.
AID528195Selectivity ratio, ratio of IC50 for mouse macrophage iNOS to IC50 for rat brain nNOS2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.
AID1632481Inhibition iNOS protein expression levels in LPS-induced mouse RAW264.7 cells at 4 uM by Western blot analysis2016Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18
Flavonoids and biphenylneolignans with anti-inflammatory activity from the stems of Millettia griffithii.
AID1233822Reduction of Ach-mediated NO-dependent precontracted Sprague-Dawley rat mesenteric vascular artery vasorelaxation measured at 1 uM/30 mins preincubation2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Selective Acetamidine-Based Nitric Oxide Synthase Inhibitors: Synthesis, Docking, and Biological Studies.
AID338889Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as effect on NO production pretreated 1 hr before LPS challenge measured after 24 hrs2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID751339Cytotoxicity against mouse RAW264.7 cells assessed as cell viability after 24 hrs by MTS assay2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID357982Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as nitrite accumulation at 10 uM after 20 hrs by fluorimetry relative to control2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID294587Inhibition of 1ug/ml LPS-stimulated nitirc oxide accumulation in RAW 264 cells after 24 hrs2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Synthetic 2',5'-dimethoxychalcones as G(2)/M arrest-mediated apoptosis-inducing agents and inhibitors of nitric oxide production in rat macrophages.
AID1358814Inhibition of recombinant bovine eNOS using [3H]L-arginine as substrate preincubated for 15 mins followed by NADPH addition measured after 20 mins in presence of FMN/FAD by liquid scintillation counting method2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1632480Inhibition iNOS mRNA expression levels in LPS-induced mouse RAW264.7 cells at 4 uM by RT-PCR analysis2016Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18
Flavonoids and biphenylneolignans with anti-inflammatory activity from the stems of Millettia griffithii.
AID358219Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as PGE2 accumulation at 10 uM after 20 hrs by RIA relative to control2001Journal of natural products, Oct, Volume: 64, Issue:10
Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives.
AID1661307Selectivity index, ratio of IC50 for recombinant human nNOS expressed in Escherichia coli to IC50 for recombinant N-terminal His-tagged human iNOS expressed in Escherichia coli2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.
AID454665Inhibition of LPS-induced nitric oxide accumulation in mouse RAW264.7 cells2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Furo[3',2':3,4]naphtho[1,2-d]imidazole derivatives as potential inhibitors of inflammatory factors in sepsis.
AID132834Inhibitory effect of compound on the accumulation of NO2 in the culture media of RAW 264.7 cells in response to LPS2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Anti-inflammatory flavonoids and pterocarpanoid from Crotalaria pallida and C. assamica.
AID1233832Induction of NA-induced LPS-treated Sprague-Dawley rat mesenteric vascular artery vasoconstriction effect measured at 1 uM/30 mins preincubation relative to basal level2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Selective Acetamidine-Based Nitric Oxide Synthase Inhibitors: Synthesis, Docking, and Biological Studies.
AID1358831Cytotoxicity against rat C6 cells assessed as cell proliferation up to 2 mM after 48 hrs by MTT assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1358813Inhibition of recombinant mouse iNOS using [3H]L-arginine as substrate preincubated for 15 mins followed by NADPH addition measured after 20 mins in presence of FMN/FAD by liquid scintillation counting method2018European journal of medicinal chemistry, May-25, Volume: 152Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.
AID1823692Inhibition of human iNOS assessed as reduction in L-[3H]-citrulline level using L-[3H]-arginine as substrate incubated for 1 hr
AID405517Binding affinity nNOS2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Recent developments in fragment-based drug discovery.
AID428584Inhibition of bovine eNOS expressed in insect Sf9 cells assessed as residual activity at 100 uM by Griess assay relative to control2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases.
AID315123Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID751329Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced COX-2 expression at 0.5 to 2 uM incubated for 2 hrs prior to LPS challenge measured after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1661308Selectivity index, ratio of IC50 for recombinant human eNOS to IC50 for recombinant N-terminal His-tagged human iNOS expressed in Escherichia coli2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Antiglioma Activity of Aryl and Amido-Aryl Acetamidine Derivatives Targeting iNOS: Synthesis and Biological Evaluation.
AID1233820Inhibition of bovine recombinant eNOS using [3H]L-arginine substrate assessed as formation of [3H]L-citruline by liquid scintillation counting analysis2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Selective Acetamidine-Based Nitric Oxide Synthase Inhibitors: Synthesis, Docking, and Biological Studies.
AID491118Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite production at 50 uM treated 30 mins before LPS challenge measured after 24 hrs by Griess method2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Evaluation of labdane derivatives as potential anti-inflammatory agents.
AID333454Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs2004Journal of natural products, Nov, Volume: 67, Issue:11
Anti-inflammatory phloroglucinols and terpenoids from Garcinia subelliptica.
AID528193Selectivity ratio, ratio of IC50 for bovine eNOS to IC50 for mouse macrophage iNOS2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase.
AID315139Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 3.78 uM by MTT assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID337057Antiinflammatory activity in LPS/IFN-gamma-stimulated mouse N9 cells assessed as inhibition of nitric oxide production pretreated 1 hr before LPS/IFNgamma challenge2003Journal of natural products, Mar, Volume: 66, Issue:3
Anti-inflammatory constituents and new pterocarpanoid of Crotalaria pallida.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (320)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (3.44)18.2507
2000's183 (57.19)29.6817
2010's112 (35.00)24.3611
2020's14 (4.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.61 (24.57)
Research Supply Index5.80 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.30%)5.53%
Reviews3 (0.91%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other324 (98.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]